Trials / Conditions / Complement 3 Glomerulopathy (C3G)
Complement 3 Glomerulopathy (C3G)
5 registered clinical trials studyying Complement 3 Glomerulopathy (C3G) — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Chinese Adults With Kidney Disease NCT07522099 | ADARx Pharmaceuticals, Inc. | Phase 2 |
| Active Not Recruiting | An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Peg NCT05809531 | Apellis Pharmaceuticals, Inc. | Phase 3 |
| Completed | Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immun NCT05067127 | Apellis Pharmaceuticals, Inc. | Phase 3 |
| Active Not Recruiting | Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN NCT04572854 | Apellis Pharmaceuticals, Inc. | Phase 2 |
| Approved For Marketing | C3G/Primary IC-MPGN EAP NCT04729062 | Apellis Pharmaceuticals, Inc. | — |